Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
:HUMA
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.16Last Year’s EPS
-0.48Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 88.64%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress with the commercial launch of Symvess and promising developments in the pipeline, supported by strong financial performance. However, challenges such as workforce reductions and negative press were notable concerns. Despite these challenges, the positive developments and financial improvements outweigh the lowlights.Company Guidance
During Humacyte's Q1 2025 earnings call, the company detailed its strategic priorities and financial outlook. Following the FDA approval of Symvess for extremity vascular trauma, Humacyte's commercial launch has been successful, with first shipments made to three Level 1 trauma centers and 45 hospitals evaluating Symvess for VAC approval. The company reported $517,000 in revenue for Q1 2025, including $147,000 from Symvess sales, and a net income of $39.1 million, driven by a $62.3 million non-cash remeasurement of contingent earn-out liabilities. Humacyte enhanced its cash runway with $46.7 million from a public offering and expects to save over $50 million in costs through workforce reductions and other measures. Future milestones include the publication of clinical results, filing an IND for coronary artery bypass grafting, and progressing the V012 Phase 3 trial for dialysis access, aiming for a supplemental BLA filing in 2026.Successful Commercial Launch of Symvess
Humacyte commenced its commercial launch of Symvess in late February 2025, with the first commercial shipments made during the first quarter to three Level 1 trauma centers.
Strong Hospital Engagement
45 hospitals have commenced evaluation of Symvess as part of their value analysis committee (VAC) approval process, and five hospitals have already approved the purchase.
FDA IND Filing for ATEV
Plans to file an IND with the FDA for first-in-human clinical testing of the small-diameter ATEV in coronary artery bypass grafting later this year.
Financial Improvement
Net income was $39.1 million for Q1 2025, compared to a net loss of $31.9 million for Q1 2024, primarily due to an increase in the non-cash remeasurement of the contingent earn-out liability.
Extended Cash Runway
Steps taken to extend Humacyte's cash runway, including a public offering providing $46.7 million in net proceeds and cost reductions.
HUMA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HUMA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $1.32 | $1.73 | +31.06% |
Mar 28, 2025 | $2.01 | $1.96 | -2.49% |
Nov 08, 2024 | $5.26 | $5.78 | +9.89% |
Aug 13, 2024 | $6.62 | $6.65 | +0.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Humacyte (HUMA) report earnings?
Humacyte (HUMA) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is Humacyte (HUMA) earnings time?
Humacyte (HUMA) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HUMA EPS forecast?
HUMA EPS forecast for the fiscal quarter 2025 (Q2) is -0.16.